AptadelTx
@aptadel
Spin-off founded for the development RNA therapeutics to treat childhood cancer
ID: 1314915359435169793
http://aptadeltx.com 10-10-2020 13:07:35
62 Tweet
89 Followers
70 Following
#BCNHealthBooster és el programa d'acceleració per #startups de #salut dirigit per Ajuntament de Barcelona Parc Científic de Barcelona Barcelona Activa i #Biocat 🚀 En #BIOSPAIN2023, Ona Therapeutics MiMARK Diagnostics i AptadelTx compartiran la seva experiència com a participants el 2022. ➕ tuit.cat/VDq57
Núria Martí Biocat Ona Therapeutics 🟢 Marina Rigau Marina Rigau, CEO & Co-founder at MiMARK Diagnostics 🟢 Gisela Lorente, CSO at AptadelTx 🟢 Speakers: María Terrades Palomar , Director of Innovation at Parc Científic de Barcelona 📍 Speakers' corner 🕗 11,30 - 12,30 🔗biospain2023.org #BIOSPAIN2023 #AseBio #health #boost
Marina Rigau MiMARK Diagnostics Mercè de Frias Ona Therapeutics & Gisela Lorente AptadelTx share their experience in the #BCNHealthBooster program Biocat Barcelona Activa Ajuntament de Barcelona #biospain
Parc Científic de Barcelona MiMARK Diagnostics Ona Therapeutics AptadelTx Biocat Barcelona Activa Ajuntament de Barcelona 👏🏽👏🏽👏🏽💪🏿💪🏿💪🏿 Os queremos a todas en EJE&CON
montse basora Parc Científic de Barcelona Continuem amb una #taularodona moderada per Núria Martí, directora d'innovació de @biocat_cat. Debatem sobre el potencial del #BCNHealthBooster amb representants i referents del sector: 🔷 Mercè de Frias d'Ona Therapeutics 🔷 Marina Rigau de MiMARK Diagnostics 🔷 Gisela Lorente d'AptadelTx
🔛 #BCNHealthBooster is a success! The program accelerates #health companies by offering access to a lab in the Parc Científic de Barcelona & training by #Biocat 💬 María Terrades, DG of PCB, said at #BIOSPAIN2023 that "looking at the outstanding indicators, it's time to think in the next edition".
💡 In 2022 the accelerator selected 11 companies having impact projects: AptadelTx, DAN*NA, Bioliquid Innovative Genetics, SL., deepull, GAT BIOSCIENCES S.L, GAT Therapeutics, MiMARK Diagnostics, Nuage Therapeutics, ONA Therapeutics, Zymvol Biomodeling Biomodeling & One Chain Immunotherapeutics.
AptadelTx DAN*NA MiMARK Diagnostics Zymvol Biomodeling One Chain Immunotherapeutics Núria Martí BIOSPAIN Parc Científic de Barcelona Barcelona Activa Ajuntament de Barcelona Marina Rigau 💬 Mercè de Frias, PhD, MBA, COO Ona Therapeutics: “At the moment when we got awarded our team was growing. The program helped us consolidate it”.
AptadelTx DAN*NA MiMARK Diagnostics Zymvol Biomodeling One Chain Immunotherapeutics Núria Martí BIOSPAIN Parc Científic de Barcelona Barcelona Activa Ajuntament de Barcelona Marina Rigau Ona Therapeutics 💬 Gisela Lorente, CSO AptadelTx: “The program allowed us perform our own science and not having to rely that much in external sources”.
AptadelTx DAN*NA MiMARK Diagnostics Zymvol Biomodeling One Chain Immunotherapeutics Núria Martí BIOSPAIN Parc Científic de Barcelona Barcelona Activa Ajuntament de Barcelona Marina Rigau Ona Therapeutics 💬 Marina Rigau, CEO & Co-founder MiMARK Diagnostics: “I really appreciate the training offered by the program and specially the fact that trains the whole team and to just the C Levels”.
🔛 El programa #BCNHealthBooster és un èxit! 💬 María Terrades Palomar, CEO del Parc Científic de Barcelona, ha confirmat a #BIOSPAIN2023 que "veient els indicadors destacats, és hora de començar a pensar en la propera edició del programa". Més detalls 👇🔗 biocat.cat/ca/noticies/le…
🗣️Núria Martí (#Biocat), ha conversat amb les representants de 3 de les startups seleccionades Ona Therapeutics, AptadelTx i MiMARK Diagnostics i ha assegurat que “al llarg dels propers dos anys, seguirem ajudant a les empreses a aconseguir el seu màxim potencial”
#PCBCommunity | Gisela Lorente, cofounder & former CSO of @Aptadel is appointed new company CEO The #spinoff from IDIBELL focuses on developing #RNAtherapies platform for #childhoodcancer using #aptamer technology Sarcomas IDIBELL Oscar Martinez Fundación Alba Pérez pcb.ub.edu/en/gisela-lore…
New investment in research on Ewing's sarcoma‼️ IDIBELL's spin-off AptadelTx Therapeutics receives funding from Little Warrior Foundation 🎗 to develop RNA-based molecules🧬to find alternative treatments that are more effective and less toxic than current ones More: idibell.cat/en/2025/01/new…
🟢 Dr. Gisela Lorente, CEO, AptadelTx 🟢 Dr. Héctor Pérez Montoyo, COO & Head of R&D, AbilityPharma 🟢 Jordi Fàbrega, Co-Founder & CEO, CONNECTA Therapeutics
